published meta-analysis   sensitivity analysis   studies

anti-inflammatory therapies in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsShi, 2020 0.53 [0.01; 27.55] Shu, 2020 0.38 [0.02; 8.14] 0.43[0.04; 4.86]Shi, 2020, Shu, 202020%141moderatenot evaluable deathsdetailed resultsShi, 2020 0.53 [0.01; 27.55] Shu, 2020 0.38 [0.02; 8.14] 0.43[0.04; 4.86]Shi, 2020, Shu, 202020%141moderatenot evaluable clinical deteriorationdetailed resultsShu, 2020 0.27 [0.01; 5.58] 0.27[0.01; 5.58]Shu, 202010%41NAnot evaluable clinical improvementdetailed resultsShu, 2020 10.27 [1.17; 90.18] 10.27[1.17; 90.18]Shu, 202010%41NAnot evaluable clinical improvement (14-day)detailed resultsShu, 2020 10.27 [1.17; 90.18] 10.27[1.17; 90.18]Shu, 202010%41NAnot evaluable clinical improvement (28-day)detailed resultsShu, 2020 3.68 [0.18; 75.54] 3.68[0.18; 75.54]Shu, 202010%41NAnot evaluable clinical improvement (7-day)detailed resultsShu, 2020 6.72 [1.50; 30.07] 6.72[1.50; 30.07]Shu, 202010%41NAnot evaluable mechanical ventilationdetailed resultsShu, 2020 0.59 [0.02; 14.04] 0.59[0.02; 14.04]Shu, 202010%41NAnot evaluable serious adverse eventsdetailed resultsShi, 2020 1.08 [0.04; 32.96] 1.08[0.04; 32.96]Shi, 202010%100NAnot evaluable adverse eventsdetailed resultsShi, 2020 0.88 [0.38; 2.03] Shu, 2020 2.48 [0.05; 132.54] 0.92[0.41; 2.09]Shi, 2020, Shu, 202020%141moderatenot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-03-28 23:04 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615 - roots T: 290